National registry for patients with moderate-to-severe atopic dermatitis in Germany

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a national clinical registry for patients suffering from moderate-to-severe atopic dermatitis (AD) in Germany. Patients will be followed for at least 24 months, during which their clinical data, treatment decisions, and patient-reported outcomes will be systematically documented. The study includes standardized visits at baseline, 3 months, and 6 months, with additional visits based on treatment changes. Optional biosamples will be collected for molecular analyses to enhance understanding of the disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* AD according to the United Kingdom (UK) working party diagnostic criteria
* Moderate to severe AD
* Objective SCORAD \> 20 or Currently anti-inflammatory systemic treatment for AD or Previous anti-inflammatory systemic treatment for AD within past 24 months

Exclusion Criteria:

\-

Where it's running

• Clinics for Dermatology, Allergy and Venerology, Hannover Medical School
  Hanover, Lower Saxony, Germany Recruiting
• Department of Dermatology, UniversityAllergyCenter, Medical Faculty Carl Gustav Carus, TU Dresden
  Dresden, Saxony, Germany Recruiting
• Head Centre for Inflammatory Skin Diseases, Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel
  Kiel, Schleswig-Holstein, Germany Recruiting

Study contacts

• Principal investigator: Jochen Schmitt, Prof.Dr. — Center for Evidence-based Healthcare, Technical University Dresden
• Study coordinator: Jochen Schmitt, Prof.Dr.
• Email: jochen.schmitt@uniklinikum-dresden.de
• Phone: +493514586493

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• A Phase 3 test of Rezpegaldesleukin (NKTR-358) for moderate-to-severe atopic dermatitis in patients 12 years and older

  This Phase 3 study tests whether Rezpegaldesleukin helps people aged 12 and up with moderate-to-severe atopic dermatitis compared to placebo.

  Recruiting at 13 sites Phase 3 Nektar Therapeutics · Birmingham, Alabama and 12 other locations · NCT07711418

• Rezpegaldesleukin for moderate-to-severe atopic dermatitis in people 12 and older

  This study tests whether Rezpegaldesleukin helps people aged 12 and up with moderate-to-severe atopic dermatitis compared with a placebo.

  Recruiting at 20 sites Phase 3 Nektar Therapeutics · Phoenix, Arizona and 19 other locations · NCT07690371

• Nemolizumab for infants with moderate-to-severe atopic dermatitis

  This study tests whether nemolizumab can be safely given to infants aged 6 to under 24 months to help manage moderate-to-severe eczema when topical treatments alone aren’t enough.

  Recruiting Phase 2 Galderma R&D · San Antonio, Texas · NCT07660835

• SYX-5219 in healthy adults and adults with moderate-to-severe atopic dermatitis

  This trial will test oral SYX-5219 in healthy adults and in adults with moderate-to-severe atopic dermatitis to see if it is safe, well tolerated, and how the drug is processed in the body.

  Recruiting at 12 sites Phase 1 Sitryx Therapeutics Ltd · Arkansas City, Arkansas and 13 other locations · NCT07558668

• Oral LW402 for moderate-to-severe atopic dermatitis

  This phase 3 study tests whether oral LW402 tablets can help adults with moderate-to-severe atopic dermatitis compared with a placebo.

  Recruiting Phase 3 Shanghai Longwood Biopharmaceuticals Co., Ltd. · Beijing · NCT07370909

• SHR-1905 treatment for moderate-to-severe atopic dermatitis

  This trial will test whether SHR-1905 injections help adults aged 18–75 who have moderate-to-severe atopic dermatitis.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Guangzhou, Guangdong · NCT07211542

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.